Muscle preservation during GLP-1 treatment: when protocol beats pharmacology

The paradox of GLP-1 agonist therapy dissolves with precision: when patients receive comprehensive counseling on protein quantity and systematized resistance training, lean mass loss drops to insignificant levels. Peter Attia explores in this AMA session how the catastrophist narrative around GLP-1 and skeletal muscle overlooks controllable variables that the disciplined patient can optimize from day one of treatment. The mechanism is direct—dietary protein and mechanical tension are primary stimuli for myofibrillar synthesis—but it requires abandoning the passive patterns that characterize conventional weight loss. For the longevity-curious reader interested in losing weight without sacrificing muscle capital, the message is liberating: it's not an irreversible side effect, but a question of protocol design.